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Abstract
Background: Nitrogen-containing bisphosphonates (BIS) are potent therapeutics in osteoporosis, but their use may
result in osteonecrotic side-effects in the maxillofacial region. Periosteal microcirculatory reactions may contribute to
the development of bone-healing complications, particularly in osteoporotic bones, where ischemia–reperfusion (IR)
events often develop during orthopaedic/trauma interventions. The effect of BIS on the inflammatory reactions of
appendicular long bones has not yet been evaluated; thus, we aimed to examine the influence of chronic zoledronate
(ZOL) administration on the periosteal microcirculatory consequences of hindlimb IR in osteopenic rats.
Materials and methods: Twelve-week-old female Sprague–Dawley rats were ovariectomized (OVX) or sham-operated,
and ZOL (80 μg/kg iv, weekly) or a vehicle was administered for 8 weeks, 4 weeks after the operation. At the end of the
pre-treatment protocols, 60-min limb ischemia was induced, followed by 180-min reperfusion. Leukocyte-endothelial
interactions were quantitated in tibial periosteal postcapillary venules by intravital fluorescence videomicroscopy.
CD11b expression of circulating polymorphonuclear leukocytes (PMN, flow cytometry) and plasma TNF-alpha
levels (ELISA) were also determined. Two-way RM ANOVA followed by the Holm–Sidak and Dunn tests was used
to assess differences within and between groups, respectively.
Results: Limb IR induced significant increases in PMN rolling and firm adhesion in sham-operated and OVX rats,
which were exacerbated temporarily in the first 60 min of reperfusion by a ZOL treatment regimen. Postischemic
TNF-alpha values showed a similar level of postischemic elevations in all groups, whereas CD11b expression only
increased in rats not treated with ZOL.
Conclusions: The present data do not show substantial postischemic periosteal microcirculatory complications
after chronic ZOL treatment either in sham-operated or OVX rats. The unaltered extent of limb IR-induced local
periosteal microcirculatory reactions in the presence of reduced CD11b adhesion molecule expression on circulating
PMNs, however, may be attributable to local endothelial injury/activation caused by ZOL.
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Introduction
Osteoporosis affects more than 75 million people world-
wide [1], with every other woman and every fifth man over
50 years suffering an osteoporotic fracture of the extrem-
ities during her or his remaining lifetime [2]. Ischemia–re-
perfusion (IR) often takes place in the affected tissue, e.g.
due to use of a tourniquet or other temporary occlusive
devices and techniques during trauma surgeries. In these
cases, IR can lead to unwanted complications through the
development of an antigen-independent inflammatory
process, which involves the activation and adhesion of
polymorphonuclear (PMN) leukocytes in the periosteal
endothelium [3] and the upregulation of several
danger-associated molecular pattern-related pathways in
the locally affected and contralateral limbs as well [4]. Pro-
inflammatory cytokines (e.g. TNF-alpha, IL-1 and IL-6)
typically reach peak values after fracture operations [5],
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and it is suggested that these proinflammatory reactions
may critically influence the process of bone regeneration.
Bisphosphonates (BISs) are potent therapeutic agents
that ameliorate the osteoporosis-induced decrease of
bone mineral density [2, 6]. Further, it has been shown
that the risk of osteoporotic fractures can be reduced, in
particular with the use of zoledronic acid (ZOL) [2, 7].
Nevertheless, BIS-induced unwanted, necrotic reactions
may also be present in the skeletal system. Specifically,
chronic BIS treatment can effectively enhance the in-
corporation of bone implants in appendicular bones [8,
9], but the likelihood of osteonecrotic complications also
increases in parallel at the jaw bones [2, 10, 11]. The in-
cidence of necrosis is especially high in the mandible
after oral surgical interventions, leading to a condition
termed medication-related osteonecrosis of the jaws. An
exact pathogenesis of this complication is still un-
known, but it seems to affect the appendicular and
axial bones differently [12, 13]. Previously, we have
also shown that BISs can induce significant inflamma-
tory reactions in the mandibular periosteum after
tooth extractions, while the microcirculation in the
tibial region remained unaffected [14].
The aim of the present study was to examine the ef-
fects of chronic BIS treatment on the postischemic peri-
osteal microcirculatory changes of the lower extremities.
To our knowledge, the possible modulator role of BIS
on the inflammatory reactions of the appendicular bones
disposed to IR injuries has not yet been evaluated. Based
on the relevant literature data and our previous results,
our null hypothesis was that ZOL treatment does not in-
fluence the periosteal microcirculatory reactions of tran-
sient limb IR. We tested this hypothesis in a clinically
relevant model of osteoporosis where anaesthetized rats
were challenged with standardised limb IR in the pres-
ence or absence of chronic ZOL treatment.
Materials and methods
All studies were carried out on Sprague–Dawley rats
housed in an environmentally controlled room with a
12-h light–dark cycle. The animals were kept on com-
mercial rat chow (Charles River, Wilmington, MA, USA)
and tap water ad libitum.
The project was approved by the National Scientific
Ethics Committee on Animal Experimentation (National
Competent Authority) under licence number V./144/
2013. The study was performed in compliance with EU
Directive 2010/63/EU on the protection of animals used
for experimental and other scientific purposes and the
National Institutes of Health guidelines on the use of ex-
perimental animals. Animal welfare-related assessments
and interventions were carried out prior to and during
the experiments.
Experimental protocol
Ovariectomy
Ovariectomy (OVX) is a well-established animal model of
osteoporosis sharing many similarities with the human
condition including increased rate of bone turnover, rela-
tively rapid bone loss and most importantly, similar skel-
etal responses to treatments used in humans (e.g.
oestrogen, calcitonin and BISs) [15, 16]. In our study,
12-week-old female rats (weighing 180 to 200 g) were
randomly allocated to ovariectomized (N = 32) or
sham-operated (N = 30) groups under anaesthesia admin-
istered intraperitoneally by a combination of ketamine
and xylazine (25mg kg−1 and 75mg kg−1, respectively). As
conditions were sterile, a median laparotomy was per-
formed and the connection of the Fallopian tubes cut be-
tween haemostats. The ovaries were then removed and
the stumps ligated with a 3-0 non-absorbable thread (Ethi-
bond Excel®, Ethicon, Somerville, NJ, USA). Thereafter,
the abdomen was filled with warm sterile physiological sa-
line, and the abdominal wall was closed with a 4-0 absorb-
able suture and a 4-0 non-absorbable suture (Vicryl® and
Prolene®, Ethicon, Somerville, NJ, USA) in two layers.
Sham-operated animals underwent identical procedures,
except of course that the Fallopian tubes and ovaries were
not touched.
Experimental protocol, experimental groups
Five weeks after OVX (i.e. at 17 weeks of age) (see Fig. 1),
a chronic zoledronate treatment was initiated in 16 ani-
mals (OVX + BIS group) with 14 of the sham-operated
animals serving as negative controls (Sham + BIS group).
ZOL (80 μg kg−1 Zometa®, Novartis Europharm, Budapest,
Hungary) was administered once a week intravenously
into the tail vein under light aether anaesthesia. The
remaining OVX and sham-operated animals received
physiological saline in the same volume (OVX + vehicle
and sham + vehicle groups, n = 16 each). These weekly in-
jections were continued for 4 weeks. At the end of the ex-
perimental protocol (in week 21), all of the animals were
subjected to a 60-min complete hindlimb ischemia
followed by a 180-min reperfusion period. Limb ischemia
was induced by applying a tourniquet around the thigh
and placing a miniclip on the femoral artery. The ex-
periments were performed in two experimental series.
In series 1, the periosteal microcirculation was exam-
ined using fluorescence intravital microscopy (IVM) at
baseline and every 60 min during the 180-min reperfu-
sion period (n = 7–9 per group). In the second experi-
mental series, blood samples from the carotid artery
were taken at baseline and during the reperfusion
period to detect changes in the plasma concentrations
of TNF-alpha and in the expression of the adhesion
molecule CD11b (n = 7 in each group). It was necessary
to separate the two series to avoid any interference
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between the fluorescent dyes used for IVM and acquisi-
tion techniques used with flow cytometry.
Surgical procedure for intravital microscopic examination of
the periosteal microcirculation
The animals were anaesthetized intraperitoneally with
an initial dose of sodium pentobarbital (45 mg kg−1).
After tracheal intubation, one of the jugular veins was
also cannulated to administer fluid and drugs (supple-
mentary dose of sodium pentobarbital, 5 mg kg−1). Dur-
ing the surgical procedures and investigation, the rats
were placed in a supine position on a heating pad to
maintain body temperature at 36–37 °C.
Under an operating microscope at × 4 magnification,
the anteromedial surfaces of the tibial periosteum and the
femoral artery on the same hindlimb were exposed with
an atraumatic microsurgical technique [3]. The limbs were
positioned horizontally on a special stage to expose peri-
osteal vessels suitable for intravital fluorescence micros-
copy (IVM) in different phases of the experiment. At the
end of the experiment, the animals were sacrificed with an
overdose of sodium pentobarbital.
Intravital video microscopy
Leukocyte−endothelial cell interactions are decisive
events among the complications of IR injury. After an
initial low affinity interaction (i.e. rolling), a higher affin-
ity binding (firm adhesion) takes place between the
PMN and the endothelial surface. These dynamic cellu-
lar reactions can be detected in real time using IVM. In
our model, the tibial periosteum was superfused with 37
°C saline, and the microcirculation was visualised by
IVM (Zeiss Axiotech Vario 100HD microscope; Carl
Zeiss GmbH, Jena, Germany, 100-W HBO mercury
lamp, Acroplan 20x water immersion objective). Fluores-
cein isothiocyanate-labelled erythrocytes (0.2ml intraven-
ously; Sigma, St. Louis, MO, USA) were used to stain red
blood cells, and rhodamine-6G (0.2%, 0.1 ml intraven-
ously; Sigma, St. Louis, MO, USA) was used to label leu-
kocytes [3]. The images from three to four fields of the
tibial periosteum were recorded with a charge-coupled de-
vice video camera (Teli CS8320Bi, Toshiba Teli Corpor-
ation, Osaka, Japan), which is attached to an S-VHS video
recorder (Panasonic AG-MD 830; Matsushita Electric In-
dustrial Co., Tokyo, Japan) and a personal computer.
Video analysis
Quantitative evaluation of the microcirculatory parame-
ters was performed offline by frame-to-frame analysis of
the videotaped images (IVM; Pictron, Budapest,
Hungary). Leukocyte–endothelial cell interactions were
analysed in at least four postcapillary venules per rat.
Rolling leukocytes were defined as cells moving with a
velocity of less than 40% of that of the erythrocytes in
the centreline of the microvessel passing through the ob-
served vessel segment within 30 s and are given as the
number of cells per millimetres per second. Adherent
leukocytes were defined as cells that did not move or de-
tach from the endothelial lining within an observation
period of 30 s and are given as the number of cells per
square millimetre of endothelial surface, calculated from
the diameter and length of the vessel segment [17].
Biochemical measurements
Immune labelling and flow cytometric analysis of CD11b
expression of neutrophil leukocytes
Leukocyte–endothelial cell interactions are dependent
upon simultaneously increased expression of adhesion
Fig. 1 Time sequence of interventions and treatments. Rats were sham-operated or ovariectomized (OVX) at the age of 12 weeks. Five weeks
later (on week 17), chronic bisphosphonate (BIS, once a week in a dose of 80 μg kg−1 in the tail vein) or saline vehicle (Veh) treatment
was initiated. At the end of the protocol (week 21), 60 min of limb ischemia followed was induced by 180 min reperfusion (IR), and
periosteal microcirculatory measurements by fluorescence intravital microscopy (IVM; series 1, n= 7–9) were conducted as well as sampling for leukocyte
adhesion molecule CD11b expression and serum TNF-alpha measurements (series 2, n= 7 each)
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molecules on the surfaces of PMNs and those of the ac-
tivated endothelia. The firm adhesion step is mediated
by PMN-derived ß2 integrins (i.e. CD11a, b, c/CD18)
which bind to various integrin receptors (intercellular
adhesion molecules-1 and intercellular adhesion
molecules-2 and vascular adhesion molecule-1) of the
endothelium [18]. An increased expression of CD11b on
PMNs in the systemic circulation can be detected after
limb IR [3]. In the present study, these changes were de-
termined from the peripheral blood by flow cytometry in
duplicate samples. One hundred microlitres of whole
blood was incubated with 20 μl of FITC-conjugated
mouse anti-rat CD11b monoclonal antibody (BD Phar-
mingen, San Jose, CA, USA) for 20 min. Negative con-
trols were obtained by omitting the antibody. The cells
were then washed twice in Hanks’ buffer and centrifuged
for 5 min at 13,500 rpm, and the pellet was resuspended.
The erythrocytes were lysed with a lysing kit (Biodesign,
Saco, ME, USA), after which the cells were washed twice
again (5 min, 6000 rpm) and resuspended in 750 μl of
Hanks’ buffer. Computer-assisted FACStar Plus Becton
Dickinson equipment was used for cytometry; the granu-
locytes were gated on the basis of their characteristic
forward and side-scatter features. Generally, 10,000
events per sample were collected and recorded; the per-
centage of labelled (activated) granulocytes (relative to
the overall marker-bearing cells) and the mean fluores-
cence intensity (average marker density) were calculated.
Detection of plasma level of TNF-alpha levels
The rest of the blood samples (0.5 ml) were centrifuged
for 5 min at 4 °C at 13,500 rpm and then stored at 70 °C
until assay. Plasma TNF-apha concentrations were deter-
mined in duplicate with a commercially available ELISA
kit (Quantikine ultrasensitive ELISA kit for rat
TNF-alpha; R&D Systems Inc., Minneapolis, MN, USA).
The minimum detectable level was less than 5 pgml-1,
and the inter-assay and intra-assay coefficients of vari-
ation were less than 10%.
Statistical analysis
Data analysis was performed with a statistical software
package (SigmaStat for Windows, Jandel Corporation,
San Rafael, CA, USA) using nonparametric methods.
Two-way RM ANOVA followed by the Holm–Sidak and
Dunn tests was used to assess differences within and be-
tween groups, respectively. Data are presented as mean
value and SEM in all figures. P values < 0.05 were con-
sidered significant.
Results
Chronic ZOL treatment did not influence baseline
values of leukocyte–endothelial interactions in the peri-
osteal microcirculation (Fig. 2a, b). IR, however, induced
significant increases in both PMN rolling and adhesion
during the entire reperfusion period, and these changes
reached a similar level in sham-operated and ovariecto-
mized rats. BIS treatment caused a temporary increase
in leukocyte rolling in OVX + IR animals and, similarly,
an earlier rise in PMN adhesion in both sham + IR and
OVX+IR animals at 60 min of reperfusion but did not
influence PMN–endothelial interactions in later stages
of reperfusion.
As compared to baseline, TNF-alpha values showed
marked increases during the reperfusion period under
examination (Fig. 3). No differences could be traced
among the different experimental groups.
In comparison to baseline values, the amount of adhe-
sion molecule CD11b on the PMN surface significantly
increased in saline-treated sham-operated and OVX rats
during reperfusion (Fig. 4a, b). In animals that received
chronic BIS treatment, however, this elevation reached a
significantly lower level.
Discussion
BISs are effective medications for bone metastases and
osteoporosis and promising treatment modalities for
complex regional pain syndrome upon fracture healing
[19–21]. The use of ZOL has been shown to have a posi-
tive effect on spinal fusion [22] and to promote osseoin-
tegration and fixation of dental implants in autologous
bone grafts in osteoporosis [23]. The periapical
lesion-induced bone loss in the mandible was effectively
ameliorated [24], and osseointegration of titanium im-
plants in postmenopausal osteoporosis was promoted by
ZOL [9]. Furthermore, ZOL brought about periosteal
bone formation after tooth extraction in osteopenic
sheep [25]. ZOL treatment, however, also induced react-
ive periosteal hypertrophy and even BIS-related osteo-
necrosis of the jaw in the same osteopenic sheep model
[26]. Nevertheless, the effect of BIS on IR-induced local
and systemic inflammatory reactions has not been exam-
ined elsewhere in an osteopenic model.
It is noteworthy that both anti- and proinflammatory
effects have been attributed to different BIS compounds.
The anti-inflammatory aspects of BISs include upregula-
tion of the number of inflammatory monocytes [27],
modulation of the proliferation and the viability and
apoptosis of monocytes and macrophages [28, 29] and a
downregulation of proinflammatory cytokines, such as
TNF-alpha [30, 31], as well as other cytokines, such as
IL-1, IL-6 and neurogenic growth factor [20]. Similarly,
inhibitory effects of BIS against neurogenic inflammation
have also been reported [20]. On the other hand, an
acute phase response (< 3 days) was induced by different
BISs including ZOL with increased TNF-alpha release in
patients [32], but tissue accumulation of PMNs, in-
creased TNF-alpha release and marked oxidative stress
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were also demonstrated in other tissues, such as the gin-
giva [33] and the liver [34] in animal models. Further-
more, priming of immunological reactions was also
attributed to ZOL [35]. BISs cause ocular inflammatory
complications in some clinical cases [36] and healing
complications of the jawbones after invasive dental inter-
ventions even leading to osteonecrosis [10]. ZOL has
been shown to aggravate kidney damage (by increasing
cytokine production, metabolic acidosis and apoptosis)
during IR injury in rats [37].
Enhanced leukocyte–endothelial interactions have
been demonstrated after BIS treatment in an arthritis
model in mice, but little is known on the ZOL-induced
periosteal microcirculatory reactions [38]. Previously, we
demonstrated that chronic BIS treatment induces some
level of microcirculatory inflammation in the mandible,
but such effects were not observed in the tibial perios-
teum [14]. Therefore, in this study, we tested the effect
of chronic ZOL treatment in a tourniquet-induced limb
ischemia model, where the role of PMN–endothelial in-
teractions in the development of postischemic microcir-
culatory inflammatory reactions is well established.
Here, we have shown that the reduced endogenous
oestrogen levels evoked by OVX do not predispose to
enhanced periosteal microcirculatory complications per
se [39, 40], with the results also demonstrating that,
apart from temporary exacerbation of PMN–endothelial
interactions at the early stages of reperfusion, no major
microcirculatory inflammatory risk could be detected
after chronic ZOL treatment. Oestrogen withdrawal in-
duces a release of TNF-alpha, which is involved in the
pathomechanism of osteoporotic bone loss in women
[41]; but here, we did not demonstrate between-group
differences in TNF-alpha levels in the postischemic
phase. Nevertheless, unlike humans, where increased
serum TNF-alpha levels after OVX have been observed
[42], we did not detect any differences between the base-
line TNF-alpha levels between the different experimental
groups. It should be noted that serum levels of
TNF-alpha are rather low in rats and baseline values
were close to the detection limit of the assay.
CD11b expression is a critical step for PMN adhesion to
activated endothelial cells, and we detected a reduced
IR-induced systemic PMN-derived CD11b expression
after ZOL administration. BISs have been shown to influ-
ence PMN functions which manifested in impaired PMN
chemotaxis and reactive oxygen species producing cap-
acity in vivo [43] and reduced myeloperoxidase and
NADPH oxidase activities in vitro [44, 45]. The inhibitory
Fig. 2 Changes in leukocyte rolling (a) and adhesion (b) in the tibial periosteal postcapillary venules in response to 60 min of tourniquet ischemia
(IR) followed 60, 120 and 180min of reperfusion in sham-operated (sham) and ovariectomized (OVX) rats treated with bisphosphonate (BIS) or a
saline vehicle. Here, data values are given as means ± SEM, and *P < 0.05 vs baseline. Two-way RM ANOVA was followed by the Holm–Sidak and
Dunn post hoc tests
Fig. 3 TNF-alpha levels in plasma samples at baseline and in response
to 60 min of limb ischemia followed by 120 and 180 min of
reperfusion (IR) in sham-operated (sham) and ovariectomized (OVX)
rats treated with bisphosphonate (BIS) or a saline vehicle. Here, data
values are given as means ± SEM, and *P < 0.05 vs baseline. Two-way
RM ANOVA was followed by the Holm–Sidak post hoc test
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effect of BIS was also demonstrated in other immune
cells such as macrophages [30]. In our study, ZOL re-
duced CD11b expression on the surface of circulating
PMNs but did not influence the overall adhesion of
PMNs in the periosteal postcapillary venules. This
finding can only be explained by some degree of
ZOL-induced endothelial activation and secondary
endothelium-derived adhesion molecule expression.
This possible ZOL-induced endothelial upregulation
of adhesion molecules (the endothelial counterparts of
CD11b) which might be responsible for the present
results should be further investigated.
Among other effects, BISs are known to inhibit vascu-
lar endothelial proliferation and to upregulate cellular
apoptosis [46]. Furthermore, BISs (alendronate) have
also been shown to inhibit nitric oxide synthase expres-
sion, which is an important endogenous modulator of
PMN–endothelial interactions [47]. These ZOL-induced
acute postischemic reactions affecting the endothelium
may also warrant further in-depth investigations.
In summary, BIS treatment exerted only a minor in-
fluence on limb IR-induced PMN rolling and
adhesion in the periosteum, and the PMN-derived ad-
hesion molecule (CD11b) expression on circulating
PMNs was even reduced. Further, no effect on postis-
chemic TNF-alpha release was demonstrated in
ZOL-treated rats. These results suggest that although
some level of local endothelial activation might be at-
tributable to the treatment, chronic ZOL administra-
tion does not have a major influence on the risk of
postischemic inflammatory microcirculatory complica-
tions in the tibial periosteum.
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